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The pan-Canadian Oncology Drug Review (pCODR) was established in 2010  
to provide provinces and territories with recommendations on reimbursement 
for cancer drugs. OBJECTIVES: The objective of this study was to analyze  
the recommendations made by pCODR in its first year of operation and identify 
trends. METHODS: Clinical and economic guidance reports and 
recommendations, publically accessible at www.pcodr.ca were reviewed. 
RESULTS: Since pCODR began accepting submissions in 2011, ten of twenty 
applications have received recommendations. Of the seven positive 
recommendations, one suggested a more limited patient population than  
the one requested (Votrient - metastatic renal cell carcinoma). In six  
cases (Afinitor, Halaven, Jakavi, Sutent, Yervoy, Zelboraf), positive 
recommendations for the requested population were made, conditional on cost-
effectiveness being improved to an “acceptable” level; thus encouraging 
provincial negotiations on rebates. Three negative recommendations were made 
due to: a) limitations in evidence from open-label, phase two trials (Xalkori - 
advanced non-small cell lung cancer); b) modest progression-free survival, lack 
of statistically significant overall survival, lack of quality of life data and  
poor cost-effectiveness (Votrient - soft tissue sarcoma), and; c) unclear clinical 
benefit and an unacceptable cost-effectiveness model (Treanda - relapsed/ 
refractory chronic lymphocytic leukemia). In some cases the economic reviews 
by pCODR included modifications (i.e., shortening time horizons  
and modifying dose) to the submitted model. CONCLUSIONS: The 
recommendations from pCODR offer new insights into the future of oncology 
drug reimbursement in Canada. The probability of a positive recommendation 
appears to increase with randomized controlled trials, positive overall survival 
and comparators reflecting current care. Finally, the positive recommendations 
clearly support a continued provincial product listing agreement structure that 
includes rebates to lower cost-effectiveness. The new pCODR review process 
highlights the value of strong clinical data and robust cost-effectiveness 
modeling.  
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OBJECTIVES: Our aim was to compare recommendations made by the pan-
Canadian Oncology Drug Review (pCODR) one year after its launch to other 
markets. METHODS: Publically accessible recommendations were reviewed: 
Canada (pCODR; www.pcodr.ca), UK (National Institute for Health and Clinical 
Excellence (NICE), www.nice.org.uk), Sweden (Dental and Pharmaceutical 
Benefits Agency (TLV), www.tlv.se), and Australia (Pharmaceutical Benefits 
Advisory Committee (PBAC), www.pbs.gov.au). RESULTS: pCODR had four 
product reviews in common with NICE, three with TLV, and five with PBAC. 
pCODR and NICE recommendations were most consistent; both positively 
recommended Votrient, Yervoy and Zelboraf. Inconsistency was observed for 
Halaven (pCODR = positive; NICE = negative). Compared to TLV, consistent 
positive recommendations were noted for Votrient and Yervoy, while 
inconsistency was observed for Zelboraf (pCODR = positive; TLV = negative). 
pCODR and PBAC were the least consistent; Votrient (renal cell carcinoma) 
received a positive recommendation and Votrient (soft tissue sarcoma) received 
a negative recommendation from both, Afinitor, Sutent, and Yervoy received 
positive recommendations by pCODR and negative recommendations by PBAC. 
Only two therapies were reviewed by all four groups: Votrient (renal cell 
carcinoma) which received a positive recommendation by all and Yervoy which 
received a positive recommendation by all, except PBAC. CONCLUSIONS: For 
products that were reviewed by pCODR and at least one other agency, the most 
consistency was observed with NICE. Discordance in recommendations may 
reflect process differences. For example, pCODR can positively recommend a 
product with acceptable clinical value conditional on improved cost-
effectiveness. However, the degree of improvement is not reviewed with the 
manufacturer; instead it is negotiated with the provincial reimbursement bodies. 
While other agencies, such as NICE, will specify a patient access scheme with the 
manufacturer as part of the recommendation process. In addition, pCODR is the 
only oncology-specific agency in these countries.  
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OBJECTIVES: Cancer drugs are the world's highest selling category of therapeutic 
products. Due to their premium price and budget impact several new drug 
reimbursement models have been implemented worldwide by public and private 
payers. These models have potential implications for coverage and 
reimbursement of all branded products. This study reviewed recent cancer drug 
reimbursement models and developed lessons and implications for future 
products. METHODS: Reviewed cancer drug reimbursement schemes in 
developed and emerging markets. Interviewed payers and KOLs to develop 
lessons and implications for future products. RESULTS: Public and private payers 
worldwide have implemented several new models for cancer drug 
reimbursement to manage budgets and control costs. In the U.S., private payers 
are piloting single source compendia and third party protocols (eg. P4 Oncology) 
to limit off-label use of cancer drugs. In the UK, NICE has successfully negotiated 
lower price and discounts for the first few cycles of therapy. In Italy, AIFA has 
implemented registry based patient access for cancer drugs. In India, several 
manufacturers have implemented novel pricing strategy for the first few cycles 
of therapy. In Germany, IQWIG has proposed to use correlations between 
surrogate endpoints and patient relevant outcomes to determine the value of 
cancer drugs. Due to the increased cost pressure on payers, such models are 
likely to inspire novel reimbursement schemes for other branded products. 
CONCLUSIONS: Cancer drug reimbursement models are setting new benchmark 
for payers to manage access and control costs. These models have significant 
implications for other expensive branded products.  
 
PCN144  
AN ESTIMATE OF THE HEALTH ECONOMIC BURDEN OF UNSATISFACTORY 
CERVICAL CANCER SCREENING TEST SAMPLES IN A POPULATION OF WOMEN 
BETWEEN THE AGES OF 21-65 YEARS IN THE UNITED STATES  
Stone G 
BD, Durham, NC, USA  
OBJECTIVES: Unsatisfactory cervical cancer screening cytology samples (Unsats), 
impose a high financial burden on the health care system. Unsats are important 
because they are more prevalent in women with invasive cervical cancer. The 
purpose of this study is to estimate the impact of Unsats on the cost of cervical 
cancer screening programs as well as on patient outcomes in a U.S. population of 
women. METHODS: A state-transition Markov model was used to simulate 
cervical cancer screening and follow-on treatment for a cohort of 1 million U.S. 
women (21-65 years of age). The screening algorithm used was based on current 
U.S. cervical cancer screening guidelines which call for primary cytology testing 
every 3 years for women between the ages of 21 and 65, with an HPV reflex test 
for those who have an abnormal cytology result. For women over 30, the U.S. 
guidelines recommend the option of a cytology/HPV co-test every 5 years. Other 
inputs included U.S. high-risk HPV prevalence; age-specific cervical cancer 
incidence and associated mortality; age-specific cervical cancer screening and 
treatment compliance; HPV vaccination rates; and U.S. health care resource cost 
data. RESULTS: Unsats are costly to cytology laboratories as all of the costs 
associated with reprocessing these samples must be absorbed by the labs. 
Samples for which reprocessing is unsuccessful impose a greater burden on the 
health care system in terms of the costs associated with patients returning to 
physicians’ offices for a second sample collection. Some patients who should 
return for a second collection are lost to follow-up, presenting an opportunity for 
disease progression. CONCLUSIONS: The Unsat rate associated with a cytology 
test can significantly increase the effective cost of the test. All costs need to be 
considered in order to determine the true cost of a cytology test for cervical 
cancer.  
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OBJECTIVES: For the contemporary health care, creation of patient registries is a 
crucial task; first of all they facilitate, from the evidence-based medicine 
position, the problem of introduction of new effective drugs (including biological 
drugs). The purpose of this study was to describe the first experience of creation 
a breast cancer patient registry in the Russian Federation. METHODS: As of 
24.07.2012, the Registry included 11,960 patients from 16 regions of Russia. The 
proportion of Moscow residents is 49.9%. RESULTS: It is found that only in 9.7% 
of cases included in the Registry breast cancer was detected at stage I. Most 
commonly the diagnosis was established at the following stages: IIA (27.5%), IIB 
(17.1%) and IIIA (19.9%). It is worth noting that in the regions the diagnosis of 
stage I cancer was established more frequently than in Moscow (chi-square=204, 
p<0.000). Assessment of the distribution of patients in the Registry by expression 
of estrogen and progesterone receptors (ER/PR) was performed for only 1195 
(16.7%) of cases where test results were available. Positive HER-2 status was 
found in 14.9% of patients in the Registry. In patients with stage I and stage II, a 
clear prevalence of HER-2 negative cases was found, whereas in patients with 
stage III and stage IV positive status prevailed. Hormonal anti-progesterone 
therapy was given to 1345 patients (94.7% of women with overexpression of 
estrogen and progesterone receptors). 83 patients received treatment with 
trastuzumab. This is consistent with the total number of HER-2 positive patients 
(101); the coverage is equal to 82.2% and considered sufficient. CONCLUSIONS: 
Analysis of the Registry revealed insufficient use of up-to-date immunoassays, 
including estrogens and progesterone receptors typing, it also showed that it is 
early stages of the disease when one can expect better clinical effect from the 
use of hormone therapy and biological therapy.  
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OBJECTIVES: The educational content of disease awareness raising activities 
concerning Human Papilloma Virus (HPV) vaccine that were targeted directly to 
consumers in Thailand was evaluated in terms of the pattern and quality of the 
advertised activities. METHODS: The activities targeted at Thai consumers 
during January 2006 and December 2008, via various mass media including 
television, magazines, and the internet were identified using health and HPV-
related keywords. The pattern of disease awareness raising activities was 
assessed by using content analysis method while the quality of educational 
content was appraised by two pharmacists using evidence-based publications 
and guidelines from the Cancer Institute of Thailand and medical associations 
